Altamira Therapeutics (NASDAQ:CYTO – Get Free Report) will be releasing its earnings data before the market opens on Tuesday, September 12th. Persons interested in registering for the company’s earnings conference call can do so using this link.
Altamira Therapeutics Trading Down 2.5 %
Shares of CYTO stock opened at $0.33 on Friday. Altamira Therapeutics has a 12 month low of $0.31 and a 12 month high of $13.52. The business’s 50 day moving average is $0.39 and its two-hundred day moving average is $0.93.
Hedge Funds Weigh In On Altamira Therapeutics
An institutional investor recently bought a new position in Altamira Therapeutics stock. Citadel Advisors LLC acquired a new position in Altamira Therapeutics Ltd. (NASDAQ:CYTO – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 72,931 shares of the company’s stock, valued at approximately $47,000. Citadel Advisors LLC owned about 1.04% of Altamira Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 2.33% of the company’s stock.
Altamira Therapeutics Company Profile
Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells.
- Five stocks we like better than Altamira Therapeutics
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 9/4 – 9/8
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- The Best 5 Small Cap AI Companies to Buy Now
- How to Invest in the FAANG Stocks
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.